Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Law Offices of Todd M. Garber Announces Lead Plaintiff Deadline In Class Action Lawsuit Against Abiomed Inc
The Law Offices of Todd M. Garber announced that shareholders of Abiomed Inc have until January 15, 2013 to move for lead plaintiff status in the shareholder lawsuit filed in the United States District Court for the District of Massachusetts. The lawsuit was filed on behalf of a class (the Class) comprising all purchasers of Abiomed securities between August 5, 2011 and October 31, 2012, inclusive (the Class Period). The Complaint alleges that throughout the Class Period the defendants made materially false and misleading statements regarding the Company's business, operations and financial prospects. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company was improperly marketing and/or labeling its Impella 2.5 system; (2) Abiomed's financial results would be materially impacted if the Company were either forced to stop or discontinued its improper conduct; (3) the Company lacked adequate internal and financial controls; and (4) as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.
Latest Developments for Abiomed Inc
- Abiomed Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates
- Abiomed Inc Reaffirms FY 2013 Revenue Guidance
- Abiomed Inc Announces That FDA 515i Reclassification Panel Recommends Class III Status for Temporary Ventricular Support Devices in Non-Roller Type Cardiopulmonary Bypass Blood Pumps Category
- Abiomed Inc Receives FDA IDE Approval For Use Of New Impella RP In Pivotal Clinical Study
Latest Key Developments in Advanced
- Edap Tms SA Receives CE Mark For Focal.one
- Andor Technology plc Issues FY 2013 Revenue Guidance Below Analysts' Estimates-DJ
- Boston Scientific Corp's Vercise DBS System Demonstrates Improvement In Motor Function For Patients With Parkinson's Disease
- USCOM Ltd Completes Pulsecor Asset Purchase and Acquires New BP+ Central Blood Pressure Device
- Share this
- Link this
- Digg this


Follow Reuters